Evidence map›Paper›PMID 37834886›Full record

ArticleJournal of clinical medicine2023

Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment.

Shiyuan Zhou, Yingying Zhai, Lingzhi Yan, Xiaolan Shi, Jingjing Shang, Depei Wu, Chengcheng Fu, Song Jin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shiyuan ZhouJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.ORCID 0000-0003-2992-789X
Yingying ZhaiJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Lingzhi YanJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Xiaolan ShiJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Jingjing ShangJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Depei WuJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.ORCID 0000-0002-6312-3863
Chengcheng FuJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Song JinJiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Soochow University · CN

Funding

National Key R&D Program of China 2017YFA0104502, 2017ZX09304021National Natural Science Foundation of China 81730003Natural Science Foundation of Jiangsu Province BK20161205 and BK20160342
6 · The paper itself

Abstract

backgroundMelphalan was poorly available in mainland China. The aim of this study is to explore the dose-adjusted busulfan/cyclophosphamide (BU/CY) as an alternative regimen in auto stem cell transplantation (ASCT) for multiple myeloma (MM).

methodsA total of 105 newly diagnosed MM patients undergoing ASCT during May 2012 and August 2017 were retrospectively analyzed. The BU/CY regimen was applied to 64 patients. Busulfan (9.6 mg/kg or 8.0 mg/kg in total) and cyclophosphamide (3.6 g/m

resultsAt a median follow-up of 65 (1~119) months, estimated overall survival (OS) and progression-free survival (PFS) at 104 months in the BU/CY and HDMEL groups were 35.6% vs. 20.5% (

conclusionsMM patients may also benefit from the dose-adjusted BU/CY regimen.

Indexed as

busulfancyclophosphamidemelphalanmultiple myelomaregimentransplantation

Identifiers

PMID37834886
PMCPMC10573400
OpenAlexW4387116555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.